News & Events

News


Monday January 20, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 4 SAN DIEGO , Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020 .


Sunday January 12, 2020

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx - INGREZZA® (valbenazine) Preliminary Full-Year 2019 Net Product Sales of Approximately $753 Million with Approximately 132,700 TRx SAN DIEGO , Jan.


Friday January 10, 2020

Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

Neurocrine Biosciences Owns Option to Exclusively License ACT-709478, a Clinical Stage Selective T-type Calcium Channel Blocker for the Treatment of Epilepsy Idorsia to Receive $45 Million Upfront Upon Exercise of the Option and up to $365 Million in Potential Development and Regulatory Milestone


Monday January 06, 2020

Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020

SAN DIEGO , Jan. 6, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38 th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time ( 2:30 p.m. Eastern Time ) on Monday, Jan. 13, 2020 , in San Francisco .


Monday December 02, 2019

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All

Events